lovastatin has been researched along with Erectile Dysfunction in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anscher, MS; Chang, MG; Grob, BM; Holdford, D; Mikkelsen, RB; Moghanaki, D; Mukhopadhyay, ND; Rosu, M; Sanyal, A; Skinner, V; Wang, A | 1 |
| Sinzinger, H | 1 |
| Halkin, A; Lossos, IS; Mevorach, D | 1 |
| Ameneiros Lago, E; Fernández Fernández, FJ; Pía Iglesias, G; Sesma Sánchez, P | 1 |
4 other study(ies) available for lovastatin and Erectile Dysfunction
| Article | Year |
|---|---|
Lovastatin may reduce the risk of erectile dysfunction following radiation therapy for prostate cancer.
Topics: Brachytherapy; Erectile Dysfunction; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Risk Factors | 2016 |
Side effects of statins--prevalence, relevance, consequences.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Cohort Studies; Erectile Dysfunction; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver; Lovastatin; Male; Muscular Diseases; Peripheral Nervous System Diseases; Pyridines; Risk Assessment; United States; United States Food and Drug Administration | 2002 |
HMG-CoA reductase inhibitor-induced impotence.
Topics: Anticholesteremic Agents; Enzyme Inhibitors; Erectile Dysfunction; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged | 1996 |
[HMG-CoA reductase inhibitors and sexual dysfunction].
Topics: Anticholesteremic Agents; Erectile Dysfunction; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged | 2001 |